Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv

Tedder, 1997, CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling, Annu. Rev. Immunol., 15, 481, 10.1146/annurev.immunol.15.1.481 Shan, 1995, Constitutive endocytosis and degradation of CD22 by human B cells, J. Immunol., 154, 4466, 10.4049/jimmunol.154.9.4466 Sato, 1998, CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor, Semin. Immunol., 10, 287, 10.1006/smim.1998.0121 Dorken, 1986, HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes, J. Immunol., 136, 4470, 10.4049/jimmunol.136.12.4470 Schwarting, 1985, The monoclonal antibodies alpha S-HCL 1 (alpha Leu-14) and alpha S-HCL 3 (alpha Leu-M5) allow the diagnosis of hairy cell leukemia, Blood, 65, 974, 10.1182/blood.V65.4.974.974 Sliedregt, 2001, Design and synthesis of a multivalent homing device for targeting to murine CD22, Bioorg. Med. Chem., 9, 85, 10.1016/S0968-0896(00)00224-8 Siegel, 2003, CD22-directed monoclonal antibody therapy for lymphoma, Semin. Oncol., 30, 457, 10.1016/S0093-7754(03)00240-9 Leonard, 2003, Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma, J. Clin. Oncol., 21, 3051, 10.1200/JCO.2003.01.082 Leonard, 2004, Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results, Clin. Cancer Res., 10, 5327, 10.1158/1078-0432.CCR-04-0294 Leonard, 2005, Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma, J. Clin. Oncol., 23, 5044, 10.1200/JCO.2005.13.821 Furman, 2004, Epratuzumab in non-Hodgkin's lymphomas, Curr. Treat. Options Oncol., 5, 283, 10.1007/s11864-004-0019-1 Coleman, 2003, Epratuzumab: targeting B-cell malignancies through CD22, Clin. Cancer Res., 9, 3991S Carnahan, 2003, Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties, Clin. Cancer Res., 9, 3982S Carnahan, 2007, Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab, Mol. Immunol., 44, 1331, 10.1016/j.molimm.2006.05.007 Krauss, 2005, Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymedouble dagger, Br. J. Haematol., 128, 602, 10.1111/j.1365-2141.2005.05356.x Ho, 2005, In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin, J. Biol. Chem., 280, 607, 10.1074/jbc.M409783200 DiJoseph, 2004, Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies, Blood, 103, 1807, 10.1182/blood-2003-07-2466 DiJoseph, 2005, Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22, Cancer Immunol. Immunother., 54, 11, 10.1007/s00262-004-0572-2 DiJoseph, 2006, Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma, Clin. Cancer Res., 12, 242, 10.1158/1078-0432.CCR-05-1905 Weldon, 2009, A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity, Blood, 113, 3792, 10.1182/blood-2008-08-173195 Onda, 2008, An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes, Proc. Natl. Acad. Sci. U. S. A., 105, 11311, 10.1073/pnas.0804851105 Li, 2006, Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma, Cancer Res., 66, 10586, 10.1158/0008-5472.CAN-06-1981 Bang, 2005, HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity, Clin. Cancer Res., 11, 1545, 10.1158/1078-0432.CCR-04-1939 Allen, 2002, Ligand-targeted therapeutics in anticancer therapy, Nat. Rev. Cancer, 2, 750, 10.1038/nrc903 Torchilin, 2007, Targeted pharmaceutical nanocarriers for cancer therapy and imaging, AAPS J., 9, E128, 10.1208/aapsj0902015 Sapra, 2004, Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes, Clin. Cancer Res., 10, 2530, 10.1158/1078-0432.CCR-03-0376 Sapra, 2004, Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab′ fragments, Clin. Cancer Res., 10, 1100, 10.1158/1078-0432.CCR-03-0041 Nellis, 2005, Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis, Biotechnol. Prog., 21, 221, 10.1021/bp049839z Laginha, 2008, Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer, J. Drug Target., 16, 605, 10.1080/10611860802229978 Xu, 2001, Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv, Mol. Med., 7, 723, 10.1007/BF03401962 Xu, 2002, Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes, Mol. Cancer Ther., 1, 337 Zhang, 2008, Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells, Cancer Lett., 269, 26, 10.1016/j.canlet.2008.04.024 O'Donnell, 2009, Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD), Invest. New Drugs Sapra, 2003, Ligand-targeted liposomal anticancer drugs, Prog. Lipid Res., 42, 439, 10.1016/S0163-7827(03)00032-8 Lian, 2001, Trends and developments in liposome drug delivery systems, J. Pharm. Sci., 90, 667, 10.1002/jps.1023 Kirpotin, 2006, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models, Cancer Res., 66, 6732, 10.1158/0008-5472.CAN-05-4199 de, 1996, Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes, FEBS Lett., 399, 232, 10.1016/S0014-5793(96)01335-X Dekruif, 1995, Rapid selection of cell subpopulation-specific human monoclonal-antibodies from a synthetic phage antibody library, Proc. Natl Acad. Sci. U. S. A., 92, 3938, 10.1073/pnas.92.9.3938 Gupta, 1981, Carbamyl analogs of phosphatidylcholines. Synthesis, interaction with phospholipases and permeability behavior of their liposomes, Biochim. Biophys. Acta, 663, 506, 10.1016/0005-2760(81)90178-8 Goswami, 1971, Spray detection of phospholipids on thin-layer chromatograms, J. Lipid Res., 12, 509, 10.1016/S0022-2275(20)39502-X Puri, 2008, HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents, J. Liposome Res., 18, 293, 10.1080/08982100802457377 Ames, 1960, The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid, J. Biol. Chem., 235, 769, 10.1016/S0021-9258(19)67936-6 Haran, 1993, Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases, Biochim. Biophys. Acta, 1151, 201, 10.1016/0005-2736(93)90105-9 Zhu, 2005, Surface modification of liposomes by saccharides: vesicle size and stability of lactosyl liposomes studied by photon correlation spectroscopy, J. Colloid. Interface Sci., 289, 542, 10.1016/j.jcis.2005.03.088 Rawat, 2004, Functional expression of CD4, CXCR4, and CCR5 in glycosphingolipid-deficient mouse melanoma GM95 cells and susceptibility to HIV-1 envelope glycoprotein-triggered membrane fusion, Virology, 318, 55, 10.1016/j.virol.2003.08.042 Xiong, 2010, The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin, Biomaterials, 31, 757, 10.1016/j.biomaterials.2009.09.080 Marty, 2005, Cytotoxic tumor targeting with scFv antibody-modified liposomes, Methods Mol. Med., 109, 389 Yatvin, 1978, Design of liposomes for enhanced local release of drugs by hyperthermia, Science, 202, 1290, 10.1126/science.364652 Nellis, 2005, Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification, Biotechnol. Prog., 21, 205, 10.1021/bp049840y Houck, 1987, The role of multivalency in antibody mediated liposome targeting, Biochem. Biophys. Res. Commun., 145, 1205, 10.1016/0006-291X(87)91565-8 Park, 2004, Future directions of liposome- and immunoliposome-based cancer therapeutics, Semin. Oncol., 31, 196, 10.1053/j.seminoncol.2004.08.009 Dimitrov, 2009, Therapeutic antibodies: current state and future trends—is a paradigm change coming soon?, Methods Mol. Biol., 525, 1, 10.1007/978-1-59745-554-1_1